decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / 220.6.3
Subscribe or sign in to view the full article.
Article Overview
This page presents a Medicare National Coverage Determination for FDG PET use in esophageal cancer, with effective-date updates and coverage categories organized around diagnosis, staging/restaging, and monitoring response to treatment. It is relevant to coders, billing staff, compliance teams, and clinicians who need to understand the scope of Medicare coverage guidance and the general documentation expectations tied to medical necessity.
Why This Topic Matters
Coverage determinations like this affect whether a service is payable under Medicare and how supporting records should be maintained. Readers use this guidance to understand when the policy applies and how the NCD frames the covered clinical contexts.
Article Sections
-
FDG PET for Esophageal Cancer (Various Effective Dates Below)
Introduces the Medicare coverage policy and notes the effective-date changes associated with the NCD. It sets the scope for the clinical situations addressed in the remainder of the article.
-
Requirements
Outlines the broad coverage categories addressed by the policy and the general documentation expectation for the medical record. It also indicates where Medicare says access information for the service may be communicated.
What You Will Learn
- The scope of the Medicare coverage policy for FDG PET in esophageal cancer
- How the article organizes coverage guidance by clinical use category
- What general documentation support is referenced in the NCD
- Which effective dates are associated with the policy updates
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Physicians and referring providers
- Revenue cycle professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com